New Study Shows Frog-Derived Gut Bacterium Completely Eradicates Tumours After a Single Dose!

When it comes to conventional medical break-throughs, we are not used to getting good news. However, a recently published peer-reviewed study in Gut Microbes has uncovered a previously unknown cancer-fighting bacterium isolated from amphibian and reptile gut microbiomes—delivering results that greatly exceeded modern oncology treatments.

In an immunocompetent mouse model of colorectal cancer, a single intravenous dose of Ewingella americana led to complete tumour elimination in 100% of treated animals, with no recurrence upon re-exposure to cancer cells—suggesting durable, long-term immune protection.

Even more striking, the bacterium outperformed both chemotherapy (doxorubicin, “red devil”) and immune checkpoint blockade (anti–PD-L1)—two pillars of modern cancer therapy.

What makes this discovery particularly compelling is the mechanism. E. americana is not a passive drug—it is a living, tumour-targeting organism. As a facultative anaerobe, it preferentially accumulates within the hypoxic tumour microenvironment, where it rapidly proliferates and exerts direct cytotoxic effects while simultaneously activating a broad immune response. Within hours, tumours become infiltrated with T cells, B cells, and neutrophils, accompanied by surges in key inflammatory cytokines like TNF-α and IFN-γ.

Investigators observed approximately a 3,000-fold increase in bacterial load within tumours within 24 hours, indicating highly efficient tumour homing and intra-tumoural expansion. This dual-action approach—direct tumour destruction combined with immune activation—distinguishes it fundamentally from conventional therapies, which typically rely on a single mechanism of action.

Equally notable is the safety profile observed in this preclinical model. Despite intravenous administration of live bacteria, treated animals showed no significant weight loss, no detectable organ toxicity, and no abnormalities in hematologic or biochemical parameters. The organism was rapidly cleared from circulation within 24 hours, while remaining selectively localized within tumour tissue—an unusual and highly favourable pharmacokinetic pattern.

Importantly, this was not a genetically engineered construct. E. americana is a naturally occurring bacterium, suggesting that vast, largely unexplored microbial ecosystems—particularly those of non-human species—may harbour powerful therapeutic agents.

While these results remain preclinical and require validation in human trials, the signal is difficult to ignore. A single-dose intervention achieving complete tumour eradication, durable immune memory, and superiority over established therapies represents one of the most striking outcomes reported in recent cancer research.

Nicolas Hulscher

The above article was written by Nicolas Hulscher MPH and you can read the original post of it on the exceptionally good Focal Points Courageous Discourse substack at: https://www.thefocalpoints.com/p/new-study-frog-derived-gut-bacterium. You can also read the original peer-reviewed study on this which confirms the remarkable findings at: https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2599562